公开(公告)号：US20130149319A1

公开(公告)日：2013-06-13

申请号：US13700668

申请日：2010-05-28

申请人： Jae-Seon Lee ,  Bong Cho Kim ,  Je-Jung Lee ,  Su Min Park

发明人： Jae-Seon Lee ,  Bong Cho Kim ,  Je-Jung Lee ,  Su Min Park

IPC分类号： A61K31/713 ,  C12Q1/68 ,  G01N33/68 ,  A61K39/395

CPC分类号： A61K31/713 ,  A61K39/39558 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6876 ,  G01N33/68

摘要： Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

摘要翻译： 公开了一种抗癌组合物，其包含针对WIG1和/或YPEL5的抑制剂或针对由该基因编码的蛋白质。 还提供了用于筛选抗癌剂的组合物，其包含具有与WIG1和/或YPEL5的mRNA互补的序列的核酸或由该基因编码的蛋白质的抗体。 另外，提供了筛选抗癌剂的方法，该方法包括：（A）定量分析未用抗癌剂候选物治疗的肿瘤细胞中mRNA或蛋白质水平的WIG1和/或YPEL5的表达; （B）定量分析治疗抗癌剂候选者后肿瘤细胞中mRNA或蛋白质水平的基因的表达; 和（C）与步骤（A）相比，如果在步骤（B）中基因的表达水平升高，则选择候选物。

公开(公告)号：US08809297B2

公开(公告)日：2014-08-19

申请号：US13700668

申请日：2010-05-28

申请人： Jae-Seon Lee ,  Bong Cho Kim ,  Je-Jung Lee ,  Su Min Park

发明人： Jae-Seon Lee ,  Bong Cho Kim ,  Je-Jung Lee ,  Su Min Park

IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K39/395

CPC分类号： A61K31/713 ,  A61K39/39558 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6876 ,  G01N33/68

摘要： Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

摘要翻译： 公开了一种抗癌组合物，其包含针对WIG1和/或YPEL5的抑制剂或针对由该基因编码的蛋白质。 还提供了用于筛选抗癌剂的组合物，其包含具有与WIG1和/或YPEL5的mRNA互补的序列的核酸或由该基因编码的蛋白质的抗体。 另外，提供了筛选抗癌剂的方法，该方法包括：（A）定量分析未用抗癌剂候选物治疗的肿瘤细胞中mRNA或蛋白质水平的WIG1和/或YPEL5的表达; （B）定量分析治疗抗癌剂候选者后肿瘤细胞中mRNA或蛋白质水平的基因的表达; 和（C）与步骤（A）相比，如果在步骤（B）中基因的表达水平升高，则选择候选物。